P. aeruginosa Infection Differs Between Cystic Fibrosis and Non-CF Bronchiectasis, Study Shows
Pseudomonas aeruginosa, one of the most common types of bacteria present in severe lung infections, infects cystic fibrosis (CF) patients...
Nanoparticles Therapy May Be ‘One-Size-Fits-All’ Approach for CF, Study Suggests
A potential therapy delivered through nanoparticles enables production of the normal, healthy form of the key CFTR protein in cystic...
Pancreatic Cell Transplant Program Offers New Hope to Some CF Patients
The University of North Carolina (UNC) is among only a few institutions in the United States that offers patients with inflamed pancreas...
WVU Medicine Granted CFF Accreditation for its Adult Cystic Fibrosis Program
The Adult Cystic Fibrosis Program at West Virginia University Medicine’s Mountain State Cystic Fibrosis Center was recently awarded...
Cystic Fibrosis Medications: What You Need to Know
Cystic fibrosis is a life-threatening, genetic disease that affects patients’ ability to breathe and is marked by persistent lung...
Vast Therapeutics’ Therapy Candidate BIOC51 Fares Well in Mouse Studies
Vast Therapeutics, formerly known as Novoclem Therapeutics, recently announced that the company’s first controlled nitric oxide (NO)...